After sales of 4 billion USD in 2015, the company sees strong growth for the next 5 years and a global share of about 10 % for Japanese products. The current market is governed by skin and cartilage-directed products, but will shift to products directed towards oncology, the circulatory and nervous system. The market provides opportunities for gest methods, storage and transportation devices and novel bioreactors
Nikkei Biotech, March 11, 2016
Frost & Sullivan sees cell pharmaceutical market at 10 billion USD in 2020, Japan strong